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rginine Vasopressin Receptor
ntagonists for Heart Failure
Winter Climbing to the Everest’s Tip?*
ian Paolo Rossi, MD, FACC
adova, Italy
eart failure (HF) is among the most common causes of
ospitalization, and its incidence will likely increase in an
ging population of “survivors” (1). Pharmacological treat-
ent targeted at neurohormonal activation has improved
urvival, but mortality remains substantial in patients with
F, thus warranting the search for novel therapeutic ap-
roaches. Novel agents under investigation for the treat-
ent of HF include arginine vasopressin (AVP) receptor
ntagonists (RA). Udelson et al. (2), in this issue of the
ournal, report the effects of an AVPRA, tolvaptan, on left
entricular (LV) remodeling in patients with systolic HF.
VP in Heart Failure
rginine vasopressin serves primarily to regulate the body’s
ater content and blood pressure by influencing water
xcretion by the kidney and controlling vascular tone. Its
elease is triggered by low effective blood volume and
ypernatremia. During arterial underfilling, the carotid
rtery, aortic arch, and left atrium baroreceptors sense a
ecrease in pressure and stimulate the release of AVP.
See page 2151
owever, because atrial pressures increase in patients with
F, the Henry-Gauer atrial reflex might be expected to
uppress AVP; therefore, arterial baroreceptors must over-
ide the activation of atrial receptors to maintain the
onosmotic release of AVP. Exquisitely sensitive “high” and
low” threshold hypothalamic osmoreceptors sense small
hanges in extracellular fluid osmolality and, by releasing
VP, stimulate thirst and water reabsorption at the kidney,
espectively.
The AVP acts on specific receptor (R) subtypes termed
1AR, V1BR (also known as V3R) and V2R. The adreno-
ortical V1AR mediate the aldosterone secretagogue effect of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thet
merican College of Cardiology.
From University Hospital, Padova, Italy.VP; in vascular smooth muscle cells and cardiomyocytes
he V1AR activation triggers vasoconstriction and increased
ontractility, respectively. In the anterior pituitary, V1BR
ediates the release of adrenocorticotropin release (3). The
enal collecting ducts V2R respond to AVP by increasing
ree water re-absorption (3). Essential in this cascade is the
quaporin-2 (AQP-2) water channels, which allow water
olecules to traverse the apical membrane of the principal
ells in response to the osmotic gradient generated by the
ountercurrent urinary concentrating mechanism. Plasma
VP levels correlate directly with AQP-2 expression and, in
F with high circulating AVP levels the AQP-2 protein
evels increase and become detectable in the urine, suggest-
ng that urinary AQP-2 measurement may be a marker of
he AVP activation and thereby of HF status (3).
athophysiological Considerations
atients hospitalized for HF are categorized into 2 main
roups: the first entails patients who present with systemic
ongestion, mostly as the result of systolic LV dysfunction
“cardiac” failure); the second comprises patients with pul-
onary congestion despite a preserved systolic function,
ecause of volume redistribution from the systemic to the
ulmonary circulation (“vascular” failure) (1). In both cases,
rterial underfilling triggers baroreceptor-mediated neuro-
umoral activation of the sympathetic nervous system, the
enin-angiotensin-aldosterone system, and the nonosmotic
elease of AVP.
Because over the long term these neurohumoral reflexes
ave deleterious consequences, a therapeutic strategy tar-
eted at the neurohumoral activation has been exploited.
ence, a combination of angiotensin-converting enzyme
nhibitors or AT1R blockers, aldosterone inhibitors, and
eta-blockers, represents the standard approach to treat HF,
esides diuretics and digoxin. Unfortunately, such an opti-
ized combination does not generally resolve congestion in
atients with HF, which is troublesome because persistent
ongestion predicts mortality (4). Furthermore, the ability
f loop diuretics, the mainstay of current treatment for HF
ongestion, to correct volume overload and decrease body
eight is limited by adverse effects, such as hyponatremia
nd worsening renal insufficiency.
Circulating AVP levels are elevated early on in patients
ith congestive HF; they are proportional to the severity of
F and predict cardiovascular mortality. These increased
VP levels are both paradoxical and inappropriate because
hey induce not only free water reabsorption by the kidney
espite an already edematous state, but also aldosterone
ecretion and increased systemic vascular resistance and
ulmonary capillary wedge pressure via V1AR-mediated
rterial vasoconstriction. Presumably, these effects are more
etrimental in the failing heart, which has an intrinsic
nability to tolerate small changes in load. Furthermore,
etention of water in excess of sodium may lead to hypona-
remia, which is an ominous prognostic indicator and carries
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June 5, 2007:2160–2 Editorial Commentubtle neurological defects that are reversible with correction
f the hyponatremia.
Hence, AVPRA might represent the ideal strategy to
reat congestion, as it might be expected to increase water
oss and lower filling pressures without negatively affecting
lood pressure, heart rate, electrolytes, renal function, neu-
ohormones, or clinical outcomes.
VPRAs
ntil recently, the potential benefits of AVPRA in the
reatment of HF could not be investigated for the lack of
ffective and well-tolerated nonpeptide agents. Newly de-
eloped compounds (for review, see Verbalis [5]) target-
ng the V1AR/V2R (conivaptan) or the V2R (mozavaptan,
ixivaptan, satavaptan, and tolvaptan) are now being
ested. They not only decrease congestion and correct
yponatremia but, in contrast with other neurohormonal
odulators, also prevent LV remodeling and progression of
V dysfunction.
Tolvaptan, the oral, once-daily, nonpeptide AVPRA
sed by Udelson et al. (2), binds to the V2R with a 29:1
ffinity over the V1AR (3). Like lixivaptan (6), tolvaptan,
educes edema, body weight, corrected hyponatremia (7),
owered urinary AQP-2 excretion, and increased solute-free
ater excretion in patients with HF. Unlike furosemide,
olvaptan increases renal blood flow, decreases renal vascular
esistance, improves glomerular filtration rate, and does not
ffect sodium and potassium excretion (3), thus approaching
he features of an ideal drug to correct congestion in patients
ith HF. Not unexpectedly, these favorable effects were
ssociated with thirst, polyuria, and increased urinary
requency (2).
oes Tolvaptan Improve LV Remodeling?
his question received a negative answer by Udelson et al.
2), which does not detract from the importance of the
tudy. The results are sound because of the use of state-of-
he-art study design and careful methodology for assessing
he LV changes. Moreover, negative studies are important
s they can avoid investigators from wasting time, energies,
nd resources in useless studies. Power calculations, which
re very helpful in connection with negative findings, were
urnished: the study was designed to have a reassuring
80%) power to detect a difference of 4.5 ml/m2 in LV
nd-diastolic volume. Although recruitment of a larger
umber of patients was planned, a dropout rate greater than
xpected was recorded. Thus, with the actual sample size
180 patients) and the pooled observed standard deviation,
he recorded average difference (1.74 ml/m2) favoring
olvaptan would require more than 1,000 patients to achieve
tatistical significance. Proof of statistical significance for
uch small beneficial effect would therefore require a much
arger study. The lack of significance likely reflects the
neffectiveness of tolvaptan of improving LV remodeling,
ut additional factors also could explain the negative find- sngs. The authors chose a dose of tolvaptan at the lowest
ange of the spectrum therapeutically explored so far in HF
tudies, albeit equal to that used in the ongoing long-term
utcomes trial (8). This dose was selected because of the
ack of a dose-dependency for correction of congestion, and
f the higher rate of side effects observed at higher doses
4,9). Whether a greater tolvaptan dose might reduce LV
nd-diastolic volume remains therefore to be ascertained.
An increase of AVP level was observed in the tolvaptan
roup as compared to placebo patients, which suggests
ffective AVP displacement from V2R. This result is at
ariance with a previous report, in which tolvaptan effec-
ively lowered congestion (9), suggesting that the relation-
hip between changes in AVP concentrations, presumed
ffects at the receptor level, and clinical effects is complex.
nformation on plasma tolvaptan levels, which would be of
nterest for a better understanding of the mechanisms
nderlying effective V2R blockade, was unfortunately not
vailable.
Noteworthy, AVP adversely affects LV remodeling and
he progression of HF through at least 5 actions, mostly
ccurring through V1AR, which are not blocked by
olvaptan: (1) V1AR signaling can increase vascular resis-
ance and thereby LV afterload LV; (2) V1AR signaling can
irectly cause cardiomyocyte hypertrophy, thereby directly
nfluencing LV remodeling; (3) V1AR signaling can cause
oronary vasoconstriction, thereby leading to ischemia; (4)
2R signaling can contribute to inappropriate volume
xpansion, thus increasing ventricular preload; and (5)
2R signaling can contribute to hyponatremia, an inde-
endent predictor of adverse outcome in patients with
ongestive HF (10).
Hence, no beneficial effects of tolvaptan on at least 3
echanisms, which are relevant for LV remodeling, can be
xpected. Likely, the small decrease of load-dependent
ndexes of LV remodeling observed at week 54 could be
ttributable mainly to the V2R-mediated aquaretic effects of
he drug lowering blood volume. This interpretation is
upported by the prompt disappearance of the small differ-
nce of LV end-diastolic volume between tolvaptan- and
lacebo-treated patients 1 week after tolvaptan withdrawal,
hich suggests a functional rather than a structural drug-
elated effect (2).
Theoretically, there might also be concerns on the long-
erm effects of V2R specific antagonists: competitive dis-
lacement of AVP from V2R could increase AVP plasma
evels and, therefore, enhance V1AR activation. By increas-
ng osmolality, a potent V2R antagonist also could induce
VP secretion. Indeed, most studies have reported an
ncrease in plasma AVP after administration of receptor
ntagonists. Whether this increase exerts detrimental effects
ia unblocked receptor sites remains to be demonstrated.
onetheless, data in experimental HF, and in class III and
V HF patients documented the benefit of combined if
1AR and V2R, at least acutely and short term. If V1ARignaling contributes to the pathophysiology of congestive
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Editorial Comment June 5, 2007:2160–2F, then an increase in V1AR-mediated effects during V2R
lockade might be harmful. Furthermore, V1AR signaling
an be amplified in the presence of diminished activity of
he renin-angiotensin-aldosterone system and the sympa-
hetic nervous system (10). Because patients with HF
sually are treated with agents inhibiting these systems, even
ore concern about these potential effects exists. Thus, even
f the net effect of using V2R antagonists is positive, ongoing
timulation of V1AR may work against an even greater
otential beneficial effect, which might be seen if both
eceptor sites were blocked. Further research aimed at
omparing the effects of combined V2R plus V1AR with
2R blockade not only on LV volumes, but also on LV
ypertrophy and fibrosis, is therefore necessary.
In a post-hoc analysis tolvaptan reduced the composite
nd point of death or hospitalization, after adjustment for
onfounders (2), which accords with results in renal dys-
unction or severe congestion patients in the ACTIV in
HF (Acute and Chronic Therapeutic Impact of a Vaso-
ressin 2 Antagonist [Tolvaptan] in Congestive Heart
ailure) trial (4). Although useful for generating hypothesis,
hese findings should be taken cautiously, because both
tudies were underpowered to investigate this question.
In summary, the success of treatment of HF targeted at
eurohormonal activation has narrowed the space for show-
ng further therapeutic improvement. Hence, only very large
ell-designed studies might demonstrate significant bene-
ts on survival and surrogate end points. Available data
ndicate that tolvaptan is safe and effective in correcting
ongestion without adversely affecting electrolytes status,
emodynamics, and renal function.
A large trial ongoing named EVEREST (Efficacy of
asopressin Antagonism in Heart Failure Outcome Study
ith Tolvaptan) investigates whether tolvaptan improves sur-
ival in patients with chronic HF. Mount Everest (8,848 m),
he highest mountain in the Himalayas named for the
ritish Surveyor General of India Sir George Everest, was
uccessfully climbed, for the first time, by Hillary and
orgay in 1953. More than 4,000 people had attempted to
limb Everest thereafter; 20% of them were successful,
nd more than 140 died trying, thus making the difficulties
f climbing Mount Everest legendary. Hopefully, the
VEREST study will not prove a winter attempt to climbhe Everest’s tip but rather as successful as Hillary’s and
orgay’s attempt.
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